Skip to main content

Related news

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

Related professionals

Sandra Vilaró Miranda

Sandra Vilaró Miranda

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more
Esther Batlle Borraz

Esther Batlle Borraz

Research technician
Research Group of Physical Medicine and Rehabilitation
Read more
Margarita Gratacós Viñola

Margarita Gratacós Viñola

Peripheral Nervous System
Read more
Antonio Palasi Franco

Antonio Palasi Franco

Research technician
Neurovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.